Ocular Therapeutix Inc
$ 9.49
-1.04%
24 Apr - close price
- Market Cap 2,065,895,000 USD
- Current Price $ 9.49
- High / Low $ 9.63 / 9.36
- Stock P/E N/A
- Book Value 3.03
- EPS -1.42
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.55 %
- 52 Week High 16.44
- 52 Week Low 6.23
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$26.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 | 2023-08-07 | 2023-05-08 |
| Reported EPS | -0.29 | -0.38 | -0.39 | -0.3724 | -0.29 | -0.22 | -0.26 | -0.7 | -0.35 | -0.17 | -0.26 | -0.39 |
| Estimated EPS | -0.32 | -0.37 | -0.35 | -0.28 | -0.22 | -0.24 | -0.22 | -0.19 | -0.3 | -0.29 | -0.3 | -0.26 |
| Surprise | 0.03 | -0.01 | -0.04 | -0.0924 | -0.07 | 0.02 | -0.04 | -0.51 | -0.05 | 0.12 | 0.04 | -0.13 |
| Surprise Percentage | 9.375% | -2.7027% | -11.4286% | -33% | -31.8182% | 8.3333% | -18.1818% | -268.4211% | -16.6667% | 41.3793% | 13.3333% | -50% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.32 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2026-04-25 05:39:36
Ocular Therapeutix has priced its stock offering at $475 million. This financial move is noteworthy for the company.
2026-04-24 22:38:34
Ocular Therapeutix (OCUL) shares increased by 8.2% following positive Week 52 data from its Phase 3 SOL-1 trial for AXPAXLI, showing superior durability and sustained disease control in wet AMD patients. The company also received FDA feedback supporting a single-trial approval pathway, which could expedite the NDA filing. This development significantly strengthens Ocular Therapeutix's investment narrative, with an upcoming Investor Day expected to clarify regulatory timing, cash runway, and commercialization plans.
2026-04-23 20:09:51
Ocular Therapeutix (OCUL) is currently seen as undervalued, trading at US$9.32 against an analyst price target of US$26.00, largely due to the anticipated approval of its AXPAXLI program for wet AMD. While this program presents significant revenue growth opportunities, its success hinges on clearing regulatory hurdles and managing cash flow. A contrasting DCF model suggests an even higher fair value of US$93.63, pointing to potential risks and rewards for investors.
2026-04-22 14:41:36
Ocular Therapeutix (OCUL) is trading at US$9.32, significantly below analyst price targets and intrinsic value estimates, suggesting it is undervalued. The company's valuation is heavily tied to the potential approval of AXPAXLI, a promising drug for wet AMD which could capture substantial market share. While an earnings-based fair value is US$26, a more aggressive DCF model estimates US$93.63 per share, highlighting a wide potential opportunity that depends on AXPAXLI's success and careful cash management.
2026-04-22 11:09:51
Ocular Therapeutix released new 52-week Phase 3 data for AXPAXLI in wet age-related macular degeneration, showing strong durability, disease control, and safety. The company plans to seek FDA approval with a single pivotal Phase 3 trial, aligning with current regulatory standards. This data could position AXPAXLI as a significant competitor in the retinal disease market, addressing the need for longer-acting treatments.
2026-04-22 10:40:10
Ocular Therapeutix (NASDAQ: OCUL) will host an Investor Day on June 17, 2026, in New York City, featuring senior leadership and retinal disease key opinion leaders. The event will offer both in-person and virtual access via webcast, with a replay available for 30 days. StockTitan reports a moderate positive market reaction to the news, with OCUL gaining 3.54% on the day of publication.
